ArticleCancer biomarkers : section A of Disease markers2018
lncRNA GHET1 down-regulation suppresses the cell activities of glioma.
Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prognostic significance of LncRNA GHET1 expression in various cancers: a systematic review and meta-analysis.Bioscience reports · 2019Pooled it
- Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.BMC cancer · 2021Article
- LncRNA GHET1 Promotes Hypoxia-Induced Glycolysis, Proliferation, and Invasion in Triple-Negative Breast Cancer Through the Hippo/YAP Signaling Pathway.Frontiers in cell and developmental biology · 2021Article
- ETS1-activated SNHG10 exerts oncogenic functions in glioma via targeting miR-532-3p/FBXL19 axis.Cancer cell international · 2020Article
- Roles of long non-coding RNAs in the hallmarks of glioma.Oncology letters · 2020Review
- Long non-coding RNA LBX2-AS1 enhances glioma proliferation through downregulating microRNA-491-5p.Cancer cell international · 2020Article
- Prognostic value of long non-coding RNA GHET1 in cancers: a systematic review and meta-analysis.Cancer cell international · 2020Review
- GHET1 acts as a prognostic indicator and functions as an oncogenic lncRNA in cervical cancer.Bioscience reports · 2019Article
- Identification of a putative competitive endogenous RNA network for lung adenocarcinoma using TCGA datasets.PeerJ · 2019Article
Corrections and comments
- Retraction · 2020-09-25Error in Analyses · Error in Results and/or Conclusions · Removed ·
- Retracted
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long noncoding RNAs (lncRNAs) are emerging as new modulators in cancer origination and progression. The previous study found lncRNA gastric carcinoma highly expressed transcript 1 (GHET1) was significantly up-regulation in the gastric cancer. In our present study, we studied the GHET1 expression in glioma and its effects to biological activities of glioma in vitro and vivo studies. In the clinical analysis, the results were shown that lncRNA GHET1 was significantly up-regulation and the Numb protein expression was significantly down-regulation in glioma tissues. In vitro and vivo studies, the results were shown that lncRNA GHET1 knock-down had effects to inhibit biological activities by regulation Numb and down-stream genes P53 and MMP2/9. The results suggested that GHET1 is a novel tumor oncogene by Numb in glioma. LncRNA GHET1 may serve as a potential biomarker and therapeutic target for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.